Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Sees Large Increase in Short Interest

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 51,800 shares, an increase of 254.8% from the February 28th total of 14,600 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 85,100 shares, the days-to-cover ratio is presently 0.6 days.

Fresenius SE & Co. KGaA Stock Up 0.5 %

FSNUY traded up $0.05 during midday trading on Friday, hitting $10.92. The company had a trading volume of 19,577 shares, compared to its average volume of 53,583. The stock’s 50 day moving average price is $10.13 and its 200 day moving average price is $9.44. Fresenius SE & Co. KGaA has a 52 week low of $6.57 and a 52 week high of $11.23. The company has a market capitalization of $24.40 billion, a price-to-earnings ratio of 52.00 and a beta of 1.02. The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last issued its earnings results on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The firm had revenue of $6.01 billion during the quarter. On average, research analysts anticipate that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.